{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:02:36Z","timestamp":1789434156800,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","award":["14106824"],"award-info":[{"award-number":["14106824"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018684","name":"National Health Commission of the People's Republic of China","doi-asserted-by":"publisher","award":["2023ZD0508700"],"award-info":[{"award-number":["2023ZD0508700"]}],"id":[{"id":"10.13039\/501100018684","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and liver-related morbidity. Current regulatory pathways rely on histology and long-term clinical outcomes, but repeated liver biopsy is noninvasive and poorly reproducible; regulators have signaled interest in noninvasive tests (NITs) as surrogate endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review synthesizes contemporary regulatory perspectives, the evidentiary framework for biomarker qualification, and the published performance of leading noninvasive tests (vibration-controlled transient elastography [VCTE], magnetic resonance elastography [MRE], and the enhanced liver fibrosis [ELF] test). We summarize diagnostic, prognostic, monitoring and response assessment data from cohort studies, meta-analyses and trial datasets, and outline the analytical and clinical validation steps required for reasonably likely surrogate endpoint (RLSE) qualification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Evidence shows that baseline values and longitudinal changes in liver stiffness measurement (LSM by VCTE and MRE) and ELF correlate with histological stage and predict liver-related events. VCTE offers broad accessibility and a mature outcome linkage; MRE provides superior accuracy and repeatability; ELF supplies a scalable prognostic blood signal. However, variability in measurement, limited trial-level surrogacy data, and low-event rates in pre-cirrhotic cohorts constrain definitive qualification. Composite or tiered strategies and prospective trial datasets linking on-treatment NIT changes to major adverse liver outcomes are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NITs show promise as surrogate endpoints for MASH trials, but full qualification as RLSE requires standardized assays, robust prospective evidence that treatment\u2011induced biomarker changes predict hard clinical outcomes, and close collaboration among academia, industry, and regulators.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-026-11148-7","type":"journal-article","created":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T08:00:31Z","timestamp":1789286431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges"],"prefix":"10.1007","author":[{"given":"Hye Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-9410","authenticated-orcid":false,"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wah Kheong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"issue":"3","key":"11148_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstrom H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u2013852. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.036","journal-title":"J Hepatol"},{"issue":"1","key":"11148_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/HEP.0000000000001509","volume":"84","author":"FA Anania","year":"2026","unstructured":"Anania FA, Hager R, Higgins K, Makar GA, Siegel J, Tran TT. Non-invasive tests: establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy-current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration. Hepatology. 2026;84(1):321\u2013327. https:\/\/doi.org\/10.1097\/HEP.0000000000001509","journal-title":"Hepatology"},{"issue":"6","key":"11148_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"21","key":"11148_CR4","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, Ostergaard LH, Long MT, Kjaer MS, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089\u20132099. https:\/\/doi.org\/10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"issue":"7","key":"11148_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S2468-1253(26)00077-4","volume":"11","author":"JF Cobbold","year":"2026","unstructured":"Cobbold JF, Miller H, Hallsworth K, Manousou P, Marjot T, Allison MED, et al. The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus. Lancet Gastroenterol Hepatol. 2026;11(7):616\u2013626. https:\/\/doi.org\/10.1016\/S2468-1253(26)00077-4","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11148_CR6","unstructured":"Context of Use. 2026 Biomarker Qualification Program, U.S. Food & Drug Administration"},{"issue":"Suppl 2","key":"11148_CR7","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12072-024-10661-x","volume":"18","author":"WK Chan","year":"2024","unstructured":"Chan WK, Wong VW, Adams LA, Nguyen MH. MAFLD in adults: non-invasive tests for diagnosis and monitoring of MAFLD. Hepatol Int. 2024;18(Suppl 2):909\u2013921. https:\/\/doi.org\/10.1007\/s12072-024-10661-x","journal-title":"Hepatol Int"},{"issue":"8","key":"11148_CR8","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","volume":"8","author":"FE Mozes","year":"2023","unstructured":"Mozes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704\u2013713. https:\/\/doi.org\/10.1016\/S2468-1253(23)00141-3","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"11148_CR9","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u20131082. https:\/\/doi.org\/10.2337\/dci24-0094","journal-title":"Diabetes Care"},{"key":"11148_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.01.014","author":"TC Yip","year":"2025","unstructured":"Yip TC, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.014","journal-title":"J Hepatol"},{"issue":"Suppl","key":"11148_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S0168-8278(24)00427-6","volume":"80","author":"TCY Yip","year":"2024","unstructured":"Yip TCY, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunctionassociated steatotic liver disease (MASLD). J Hepatol. 2024;80(Suppl):S2\u2013S3","journal-title":"J Hepatol"},{"issue":"2","key":"11148_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cgh.2025.07.011","volume":"24","author":"XD Zhou","year":"2026","unstructured":"Zhou XD, Li YT, Kim SU, Yip TC, Petta S, Nakajima A, et al. Longitudinal changes in fibrosis markers: monitoring stiffness\/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol. 2026;24(2):394\u2013406. https:\/\/doi.org\/10.1016\/j.cgh.2025.07.011","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"11148_CR13","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","volume":"19","author":"JG Stine","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, Wang JL, Kaulback K, Argo CK, et al. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19(11):2274-2283.e2275. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.061","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"11148_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1053\/j.gastro.2018.09.021","volume":"156","author":"R Loomba","year":"2019","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. Gastroenterology. 2019;156(1):88-95.e85. https:\/\/doi.org\/10.1053\/j.gastro.2018.09.021","journal-title":"Gastroenterology"},{"issue":"3","key":"11148_CR15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/hep.30974","volume":"71","author":"VH Ajmera","year":"2020","unstructured":"Ajmera VH, Liu A, Singh S, Yachoa G, Ramey M, Bhargava M, et al. Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease. Hepatology. 2020;71(3):849\u2013860. https:\/\/doi.org\/10.1002\/hep.30974","journal-title":"Hepatology"},{"issue":"5","key":"11148_CR16","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Anstee QM, Wai-Sun Wong V, Trauner M, Lawitz EJ, Harrison SA, et al. The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology. 2021;160(5):1608-1619.e1613. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.003","journal-title":"Gastroenterology"},{"issue":"12","key":"11148_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41575-025-01120-5","volume":"22","author":"LA Diaz","year":"2025","unstructured":"Diaz LA, Thiele M, Louvet A, Lee BP, Ajmera V, Tavaglione F, et al. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. Nat Rev Gastroenterol Hepatol. 2025;22(12):866\u2013884. https:\/\/doi.org\/10.1038\/s41575-025-01120-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"11148_CR18","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/HEP.0000000000000843","volume":"81","author":"RK Sterling","year":"2025","unstructured":"Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD practice guideline on imaging-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(2):672\u2013724. https:\/\/doi.org\/10.1097\/HEP.0000000000000843","journal-title":"Hepatology"},{"issue":"4","key":"11148_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","volume":"75","author":"EA Selvaraj","year":"2021","unstructured":"Selvaraj EA, Mozes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021;75(4):770\u2013785. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.044","journal-title":"J Hepatol"},{"issue":"12","key":"11148_CR20","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.cgh.2013.07.034","volume":"11","author":"S Singh","year":"2013","unstructured":"Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(12):1573\u20131584. https:\/\/doi.org\/10.1016\/j.cgh.2013.07.034","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"11148_CR21","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12072-019-09952-5","volume":"13","author":"Y Shen","year":"2019","unstructured":"Shen Y, Wu SD, Wu L, Wang SQ, Chen Y, Liu LL, et al. The prognostic role of liver stiffness in patients with chronic liver disease: a systematic review and dose-response meta-analysis. Hepatol Int. 2019;13(5):560\u2013572. https:\/\/doi.org\/10.1007\/s12072-019-09952-5","journal-title":"Hepatol Int"},{"issue":"4","key":"11148_CR22","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta S, Sebastiani G, Vigano M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19(4):806\u2013815. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.045","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"11148_CR23","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC, Tsochatzis E, Petta S, Bugianesi E, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331(15):1287\u20131297. https:\/\/doi.org\/10.1001\/jama.2024.1447","journal-title":"JAMA"},{"issue":"3","key":"11148_CR24","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231220","volume":"310","author":"G Moura Cunha","year":"2024","unstructured":"Moura Cunha G, Fan B, Navin PJ, Olivie D, Venkatesh SK, Ehman RL, et al. Interpretation, reporting, and clinical applications of liver MR elastography. Radiology. 2024;310(3): e231220. https:\/\/doi.org\/10.1148\/radiol.231220","journal-title":"Radiology"},{"issue":"3","key":"11148_CR25","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","volume":"79","author":"JX Liang","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H, Imajo K, Noureddin M, Behari J, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023;79(3):592\u2013604. https:\/\/doi.org\/10.1016\/j.jhep.2023.04.025","journal-title":"J Hepatol"},{"issue":"9","key":"11148_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","volume":"19","author":"T Gidener","year":"2021","unstructured":"Gidener T, Ahmed OT, Larson JJ, Mara KC, Therneau TM, Venkatesh SK, et al. Liver stiffness by magnetic resonance elastography predicts future cirrhosis, decompensation, and death in NAFLD. Clin Gastroenterol Hepatol. 2021;19(9):1915\u20131924. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.044","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"11148_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","volume":"163","author":"V Ajmera","year":"2022","unstructured":"Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, et al. Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants. Gastroenterology. 2022;163(4):1079\u20131089. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.073","journal-title":"Gastroenterology"},{"issue":"1","key":"11148_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/hep.32594","volume":"77","author":"T Gidener","year":"2023","unstructured":"Gidener T, Dierkhising RA, Mara KC, Therneau TM, Venkatesh SK, Ehman RL, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2023;77(1):268\u2013274. https:\/\/doi.org\/10.1002\/hep.32594","journal-title":"Hepatology"},{"issue":"4","key":"11148_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101351","volume":"7","author":"J Fichez","year":"2025","unstructured":"Fichez J, Mouillot T, Vonghia L, Costentin C, Moreau C, Roux M, et al. Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Rep. 2025;7(4): 101351. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101351","journal-title":"JHEP Rep"},{"issue":"10","key":"11148_CR30","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Shankar SS, Yates KP, Bolognese J, Daly E, Dehn CA, et al. Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis. Nat Med. 2023;29(10):2656\u20132664. https:\/\/doi.org\/10.1038\/s41591-023-02539-6","journal-title":"Nat Med"},{"issue":"8","key":"11148_CR31","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","volume":"8","author":"Y Vali","year":"2023","unstructured":"Vali Y, Lee J, Boursier J, Petta S, Wonders K, Tiniakos D, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. Lancet Gastroenterol Hepatol. 2023;8(8):714\u2013725. https:\/\/doi.org\/10.1016\/S2468-1253(23)00017-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"11148_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/gut.2009.203166","volume":"59","author":"J Parkes","year":"2010","unstructured":"Parkes J, Roderick P, Harris S, Day C, Mutimer D, Collier J, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010;59(9):1245\u20131251. https:\/\/doi.org\/10.1136\/gut.2009.203166","journal-title":"Gut"},{"issue":"6","key":"11148_CR33","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.cgh.2020.06.070","volume":"19","author":"VS Are","year":"2021","unstructured":"Are VS, Vuppalanchi R, Vilar-Gomez E, Chalasani N. Enhanced liver fibrosis score can be used to predict liver-related events in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Clin Gastroenterol Hepatol. 2021;19(6):1292\u20131293. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.070","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11148_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04496-2","author":"M Pavlides","year":"2026","unstructured":"Pavlides M, Vali Y, M\u00f3zes FE, Wonders K, Akhtar S, Hockings PD, et al. Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS imaging study. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04496-2","journal-title":"Nat Med"},{"issue":"1","key":"11148_CR35","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231092","volume":"309","author":"KJ Fowler","year":"2023","unstructured":"Fowler KJ, Venkatesh SK, Obuchowski N, Middleton MS, Chen J, Pepin K, et al. Repeatability of MRI biomarkers in nonalcoholic fatty liver disease: the NIMBLE consortium. Radiology. 2023;309(1): e231092. https:\/\/doi.org\/10.1148\/radiol.231092","journal-title":"Radiology"},{"issue":"1","key":"11148_CR36","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/jgh.14311","volume":"34","author":"JC Chow","year":"2019","unstructured":"Chow JC, Wong GL, Chan AW, Shu SS, Chan CK, Leung JK, et al. Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness. J Gastroenterol Hepatol. 2019;34(1):241\u2013248. https:\/\/doi.org\/10.1111\/jgh.14311","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11148-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11148-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11148-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:03:33Z","timestamp":1789430613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-026-11148-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":36,"alternative-id":["11148"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11148-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Vincent Wong has served as a consultant or advisory board member for AbbVie, Altimmune, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Merck, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, TARGET PharmaSolutions; a speaker for Abbott, AbbVie, AstraZeneca, Echosens, Gilead Sciences, Novo Nordisk; an independent non-executive director for Furui; and a co-founder for Illuminatio Medical Technology. He has received a research grant from Gilead Sciences. Wah Kheong Chan has served as a consultant or advisory board member for Abbott, AbbVie, Boehringer Ingelheim, IPSEN, Kowa, Novo Nordisk, Roche and Zuellig Pharma, a speaker for Abbott, Boehringer Ingelheim, Duopharma, Echosens, Hisky Medical, Novo Nordisk, Roche, Taisho and Viatris, and received research grant from Abbott and Roche.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}